Genryzon Drug Interactions

Genryzon Drug Interactions

Somatrogon has no direct pharmacokinetic partners, but growth hormone's physiological effects change the requirements for several classes of co-medication. Missing these adjustments causes preventable adverse events.

Step 1 — Screen the medication list at every visit

At every follow-up in a child on Genryzon, review whether they are on any of these classes:

• Glucocorticoids (any dose, any route)
• Insulin or oral hypoglycaemic agents
• Levothyroxine
• Oral estrogen (combined OCP, HRT, isolated estrogen)
• CYP3A4 substrates — sex steroids, systemic corticosteroids, anticonvulsants (esp. phenytoin, carbamazepine, phenobarbital), ciclosporin

Any hit → apply the matching Step 2 rule.

Step 2 — Class-by-class adjustment rules

Glucocorticoids

Effect of GH on the patient:

• GH decreases cortisone → cortisol conversion and may unmask previously undiagnosed central hypoadrenalism
• In an ACTH-deficient child already on hydrocortisone replacement, the same dose may become insufficient on GH
• Concurrent glucocorticoid can inhibit the growth-promoting effect of somatrogon (dose-dependent)

Action:

• Child on hydrocortisone replacement → re-review dose at 4–8 weeks after starting Genryzon; often needs dose ↑ (e.g. from 8 to 10 mg/m²/day). Reinforce sick-day rules and stress dosing
• Child on supraphysiologic glucocorticoid (asthma, IBD, autoimmune) → growth will be blunted; discuss steroid-sparing alternatives with the treating team where possible
• Any child on GH with vague fatigue / abdominal pain / hypotension → low threshold for morning cortisol and stress-dose steroids
• Never stop a glucocorticoid abruptly to "let GH work" — taper properly

Insulin and oral hypoglycaemic agents

Effect of GH:

• GH reduces insulin sensitivity and can precipitate or worsen hyperglycaemia
• Diabetic children on GH usually need more insulin once GH is started

Action:

• T1DM on insulin → expect insulin requirement to ↑ by 10–30% after starting Genryzon. Warn family, adjust rapid- and basal-insulin doses proactively, and increase glucose monitoring frequency during the first month
• T2DM on OADs → similar principle; may need dose ↑ or an additional agent (metformin usually continues; may need SU/DPP-4/other add-on)
• Non-diabetic but at risk → monitor FPG + HbA1c every 3–6 months for the first year, then annually
• Newly diagnosed diabetes on GH → involve paediatric diabetologist; do not stop GH reflexively — most cases are manageable, but the co-morbidity changes the risk-benefit balance

Levothyroxine (thyroxine)

Effect of GH:

• GH increases T4 → T3 conversion
• Can unmask previously undiagnosed central hypothyroidism — free T4 falls, TSH may be normal or inappropriately low
• Can also increase levothyroxine requirement in a child already treated for hypothyroidism

Action:

• Child on levothyroxine → recheck TSH + free T4 at 6–8 weeks after starting Genryzon and at every subsequent 6–12 month visit; titrate levothyroxine up if free T4 has fallen
• Not on levothyroxine, TSH normal at baseline → recheck TSH + fT4 at every visit; be alert for central hypothyroidism (low fT4 with inappropriately normal or low TSH)
• Untreated hypothyroidism blunts the growth response — never leave untreated on GH

Oral estrogen (OCP, HRT)

Effect of oral estrogen:

• Oral estrogen ↑ first-pass hepatic effect → ↓ IGF-1 generation → the child needs a higher somatrogon dose to hit target IGF-1 SDS
• Transdermal estrogen (patch, gel) does not have the same effect — usually no dose adjustment needed

Action:

• Female patient starting oral OCP or HRT → re-check IGF-1 (day 4 post-dose) at 6–8 weeks; expect to need a higher somatrogon dose. See genryzon-igf1-titration
• Female patient stopping oral estrogen → IGF-1 will rise; expect to reduce somatrogon dose to avoid crossing +2 SDS
• Switching from oral to transdermal → somatrogon requirement will fall; monitor
• In teenage girls on Genryzon, flag OCP status at every visit — it is often the missed cause of an unexpectedly rising or falling IGF-1

CYP3A4-metabolised drugs

Effect of somatrogon:

• Somatrogon induces CYP3A4 mRNA expression in vitro; clinical significance is not fully established
• By analogy with other GH agonists, expect ↑ clearance of CYP3A4 substrates → lower drug levels and potential loss of efficacy

Watch and adjust:

Action:

• Never assume a stable anticonvulsant or ciclosporin regimen will remain stable on GH. Recheck drug levels
• Loop the specialty team (neurology, transplant, rheumatology) into any planned Genryzon start or dose change

Step 3 — Special situations

Recent tumour or antitumour therapy

Not a drug interaction per se, but relevant to co-medication:

• Somatrogon is contraindicated in active malignancy
• Antitumour therapy must be completed before starting GH
• On-treatment scans and oncologist clearance are prerequisites

Concurrent GH-antagonist drugs

There are no formally listed antagonists in the monograph, but be aware:

• Somatostatin analogues (octreotide, lanreotide) are physiological antagonists of GH — unlikely to be co-prescribed in a child but flag if seen
• Very high-dose glucocorticoid functions as a growth-suppressor — see the glucocorticoid section

Vaccines and infections

• No specific vaccine interaction listed
• Never start Genryzon during acute critical illness or intercurrent respiratory infection (esp. in PWS)

Guardrails

• Adrenal insufficiency can be occult before GH is started — a child on glucocorticoid replacement who becomes unwell after starting Genryzon may need up-titration or stress-dose steroids
• A diabetic child starting GH is going to need more insulin, not less — warn the family up front so they are not surprised by rising glucose
• Central hypothyroidism can be masked by an "acceptable" TSH — always look at free T4 in this context
• Oral vs transdermal estrogen matters — do not treat these as equivalent when planning somatrogon dosing
• Do not assume "no known DDI" means no consequence — the CYP3A4 signal is preclinical, so therapeutic drug monitoring of anticonvulsants, ciclosporin, tacrolimus, and similar is prudent
• Loop specialty teams in early for children on immunosuppressants, anticonvulsants, or complex hormone replacement — dose management is shared care
• Document every adjustment — the reason (drug X was started, IGF-1 SDS changed to Y), the old dose, the new dose, and the recheck plan

Related MD2SKILL skills

• genryzon-prescribing-guide — starting dose and monitoring cadence
• genryzon-igf1-titration — how oral estrogen changes IGF-1 targets and titration
• genryzon-pretreatment-screening — the baseline checks that determine which of these DDI rules will apply
• genryzon-red-flag-monitoring — hyperglycaemia / adrenal insufficiency / thyroid symptoms surface here first

Source

Pfizer Products India Pvt. Ltd. GENRYZON® (Somatrogon) Solution for Injection in Pre-filled Pen — Prescribing Information (India). LPD version 2022-0081166 (PfLEET 2022-0081166). Section 4.5 "Drugs Interactions" and Section 4.4 "Special Warnings and Precautions for Use".